{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:48:39Z","timestamp":1793411319122,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1136\/ijgc-2020-002031","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T15:55:13Z","timestamp":1607010913000},"page":"59-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-2772","authenticated-orcid":false,"given":"Nalee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Suk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gun Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-002031_bb0010","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.ygyno.2007.07.025","article-title":"Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients","volume":"107","author":"Sartori","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-015-0373-0","article-title":"Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients","volume":"10","author":"Im","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0020","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2020-002031_bb0025","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0030","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaoncol.2018.2677","article-title":"Association of definitive pelvic radiation therapy with survival among patients with newly diagnosed metastatic cervical cancer","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0035","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0040","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2009.02.037","article-title":"Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer","volume":"76","author":"Crane","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-002031_bb0045","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2010.02.030","article-title":"Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer","volume":"80","author":"Small","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-002031_bb0050","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","article-title":"Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer","volume":"24","author":"Crane","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2013.10.022","article-title":"RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma","volume":"88","author":"Schefter","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-002031_bb0060","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/cncr.29337","article-title":"NRG Oncology\/RTOG 0921: a phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer","volume":"121","author":"Viswanathan","year":"2015","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2020-002031_bb0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2013.10.031","article-title":"A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer","volume":"132","author":"Viswanathan","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2009.24.7353","article-title":"Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab","volume":"28","author":"Spigel","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0075","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/JTO.0b013e3181c06a6f","article-title":"Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy","volume":"4","author":"Gore","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2006.07.005","article-title":"Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors","volume":"104","author":"Kim","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-014-0320-5","article-title":"Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis","volume":"10","author":"Yoon","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0090","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s00066-017-1178-x","article-title":"Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy","volume":"193","author":"Sturdza","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1136\/ijgc-2020-002031_bb0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ygyno.2015.10.005","article-title":"De-escalation of the cumulative central radiation dose according to the tumor response can reduce rectal toxicity without compromising the treatment outcome in patients with uterine cervical cancer","volume":"139","author":"Kim","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0100","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Statist"},{"key":"10.1136\/ijgc-2020-002031_bb0105","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2007.04.030","article-title":"Vesicovaginal fistula formation in patients with stage IVA cervical carcinoma","volume":"106","author":"Moore","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0110","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk factors for Gi adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group study","volume":"32","author":"Burger","year":"2014","journal-title":"JCO"},{"key":"10.1136\/ijgc-2020-002031_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.semradonc.2006.11.008","article-title":"Molecular mechanisms of late normal tissue injury","volume":"17","author":"Brush","year":"2007","journal-title":"Semin Radiat Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0120","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijrobp.2015.02.016","article-title":"Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy","volume":"92","author":"Pollom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-002031_bb0125","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1245\/s10434-006-9337-9","article-title":"Gastrointestinal perforation due to bevacizumab in colorectal cancer","volume":"14","author":"Saif","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2020-002031_bb0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/jsre.2001.6089","article-title":"Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation","volume":"96","author":"Howdieshell","year":"2001","journal-title":"J Surg Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24026215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24026215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-002031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:26:54Z","timestamp":1753234014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24026215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1048891X24026215"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-002031","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-002031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}